AOD-9604 research: an antilipogenic fragment that worked in mice and missed in humans.

Start here

AOD-9604 research splits into two stories. The first is a clean mechanism: in fat cells, this fragment of growth hormone slows the building of new fat. It does this by blocking acetyl-CoA carboxylase (the enzyme that starts fat synthesis) and by raising a fat-cell receptor (beta-3 adrenergic) that helps burn fat. Most of this was shown in mice, rats, and cells.

The second story is the human one, and it is short. The peptide was tested as a weight-loss pill in about 900 obese adults. It was safe. It did not work — the main trial showed no real weight loss versus a dummy pill, and the program closed. So the mechanism is real in animals, the safety record in people is reassuring, and the weight-loss promise did not hold. The sections below give each finding with its species, route, and source.

Mechanism: antilipogenic first

The foundational characterisation localised the fat-metabolism activity of human growth hormone to its C-terminal domain, the synthetic version of which is AOD-9604 ^[12]. Human growth hormone and its C-terminal part-sequence inhibit acetyl-CoA carboxylase — and therefore fatty-acid synthesis — by interacting with adipocyte and hepatocyte plasma membranes, releasing a second messenger that increases enzyme phosphorylation ^[2]. The synthetic 177-191 sequence showed antilipogenic activity identical to intact hGH, with no significant lipolytic effect measured by glycerol release from rat epididymal fat pads ^[3].

That last detail matters for honest framing: the earliest, best-characterised activity is antilipogenic (suppressing new fat synthesis), not directly lipolytic. The popular "fat-burning" framing overstates the lipolytic side of the story.

A second arm of the mechanism is the beta-3 adrenergic receptor (a fat-cell switch for energy expenditure and fat burning). In obese mice, chronic treatment raised beta-3 AR RNA expression toward lean-mouse levels; in beta-3 AR knockout mice, the long-term weight and lipolytic response was abolished, while the acute rise in energy expenditure and fat oxidation persisted ^[4]. The chronic benefit depends on that receptor; the acute one does not. Crucially, AOD-9604 does not engage the growth hormone receptor and does not raise IGF-1 — the basis for the carbohydrate-sparing, receptor-sparing design claim ^[1].

Rodent fat-metabolism data

The animal record is consistent. Chronic treatment of obese mice with human growth hormone or the modified C-terminal fragment increased fat oxidation and produced weight loss ^[1]. Long-term treatment of obese ob/ob mice with synthetic hGH 177-191 reduced cumulative body-weight gain and adipose-tissue mass and significantly inhibited lipogenesis in adipose tissue ^[8]. Metabolic studies characterised AOD-9604 as a synthetic lipolytic/antilipogenic domain of hGH, supporting the C-terminal region as the functional domain for the hormone's effects on lipid metabolism ^[12].

The glucose side of the C-terminal region was mapped too. In normal rats, synthetic peptides spanning hGH residues 172-191, 176-191, 177-191 and 178-191 produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin; the 178-191-containing peptides reduced insulin sensitivity — identifying which fragments carry the parent hormone's diabetogenic activity ^[13]. The lipolytic-fragment design deliberately avoids that liability.

AOD-9604 weight loss: the human result

This is the section the marketing avoids. Across roughly six clinical trials totalling about 900 obese subjects, oral AOD-9604 at daily doses from 0.25 mg to 54 mg (durations from 7 days to 24 weeks) showed a safety and tolerability profile indistinguishable from placebo and did not produce the adverse effects associated with full-length hGH ^[5]. Safety, yes. Efficacy, no: the pivotal Phase IIb obesity trial did not demonstrate statistically significant weight loss versus placebo, and the obesity development program was discontinued around 2007. The compound was not approved for any indication ^[9].

The pattern — strong rodent fat-metabolism data that does not translate into sufficient clinical weight loss — is common for obesity drug candidates ^[11]. Human fat loss is therefore not an established fact for AOD-9604; it is a hypothesis the pivotal trial failed to confirm.

Safety, pharmacokinetics, and cartilage work

Non-clinical evaluation found AOD-9604 free of genotoxic and toxicological concerns and generally safe after chronic oral administration in rats and primates. Pharmacokinetics showed a very short half-life of about 3 minutes after IV injection, with in vivo degradation by sequential removal of amino acids from the N-terminus in a cascade ^[7]. Oral absorption was demonstrated, which is why the human program dosed by tablet.

Beyond obesity, the most-cited secondary line is joint repair — preclinical only. In a collagenase-induced knee osteoarthritis model in 32 New Zealand white rabbits, weekly intra-articular injection of 0.25 mg AOD-9604 (with or without 6 mg hyaluronic acid) for 4-7 weeks reduced gross morphological and histopathological cartilage-degeneration scores versus saline control ^[14]. There are no published human osteoarthritis trials of AOD-9604 itself, so this remains an animal finding.